Dune Medical Devices, Inc. announced that positive interim results from a European post-market study of the MarginProbe™ System, a technology to enable better detection and removal of cancerous tissue during breast-conserving surgery (BCS), were presented at the German Breast Cancer Society Meeting (DGS 2010) held in Hamburg, Germany from July 1-3, 2010. Data presented demonstrated that use of MarginProbe during initial surgery to treat ductal carcinoma in-situ (DCIS), contributes to a fifty-percent reduction in the need for additional surgery to remove residual cancer…

Using a small molecule decoy, investigators funded by the Samuel Waxman Cancer Research Foundation have managed to block protein interactions and induce epigenetic reprogramming in human and mouse breast cancer cells, essentially changing the gene expression of breast cancer cells to behave in a more normal manner. The research illustrates what may perhaps become an effective targeted epigenetic therapy in breast cancer…

Fish oil could help prevent breast cancer, according to observational findings linking the supplements to lower breast cancer risk.

Using a small molecule decoy, researchers funded by the Samuel Waxman Cancer Research Foundation have managed to block protein interactions and induce epigenetic reprogramming in human and mouse breast cancer cells, essentially changing the gene expression of breast cancer cells to behave in a more normal manner. The research illustrates what may perhaps become an effective targeted epigenetic treatment in breast cancer. Interestingly, the targeted therapy showed exciting results in triple-negative breast cancer cells, reverting their function and appearance, and sensitizing them to tamoxifen and retinoids……..

A recent report in Cancer Epidemiology, Biomarkers and Prevention, a journal of the American Association for Cancer Research, adds to the growing evidence that fish oil supplements may play a role in preventing chronic disease. Scientists at the Fred Hutchinson Cancer Research Center in Seattle, Wash., led by Emily White, Ph.D., a member of the public health sciences division, asked 35,016 postmenopausal women who did not have a history of breast cancer to complete a 24-page questionnaire about their use of non-vitamin, non-mineral “specialty” supplements in the Vitamins and Lifestyle (VITAL) cohort study……..

In draft guidance issued today (9 July) by the National Institute for Health and Clinical Excellence (NICE), the drug bevacizumab (Avastin, Roche Products) is not recommended for use in combination with a taxane for patients whose breast cancer has spread to other parts of the body…

Rates for breast cancer screening have plateaued at just above 80% since 2000, according to Centers for Disease Control and Prevention statistics released on Tuesday, the Wall Street Journal reports. CDC’s “Vital Signs” report found that in 2008, 81.1% of women ages 50 through 74 underwent screening for breast cancer, compared with 81.5% in 2006. The national breast cancer screening rate has remained roughly stable since 2000, according to the Journal (Corbett Dooren, Wall Street Journal, 7/7)…

ATLANTA (MedPage Today) — Universal screening for colorectal cancer could prevent 32,000 deaths a year — but not enough people are being screened, according to a study of recent trends in screening for colon and breast cancer.

A novel therapy designed to attack tumors in patients with a genetic mutation in either BRCA1 or BRCA2, slowed tumor growth in 85 percent of advanced breast cancer patients treated in a small study, researchers report.

Men who carry a faulty BRCA2 gene have a 1 in 15 chance of developing breast cancer by the time they reach 70, suggests the largest study of its kind, published online in the Journal of Medical Genetics. Carriage of a faulty BRCA2 gene in women significantly increases their chances of developing breast cancer, and often at a young age. But it has not been clear whether men are susceptible, largely because few studies have been carried out, and published research has been based on retrospective data…